Wang, C.-C.; Chiu, L.-C.; Ju, J.-S.; Lin, Y.-C.; Fang, Y.-F.; Yang, C.-T.; Hsu, P.-C.
Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines 2021, 9, 1122.
https://doi.org/10.3390/vaccines9101122
AMA Style
Wang C-C, Chiu L-C, Ju J-S, Lin Y-C, Fang Y-F, Yang C-T, Hsu P-C.
Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines. 2021; 9(10):1122.
https://doi.org/10.3390/vaccines9101122
Chicago/Turabian Style
Wang, Chin-Chou, Li-Chung Chiu, Jia-Shiuan Ju, Yu-Ching Lin, Yueh-Fu Fang, Cheng-Ta Yang, and Ping-Chih Hsu.
2021. "Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study" Vaccines 9, no. 10: 1122.
https://doi.org/10.3390/vaccines9101122
APA Style
Wang, C.-C., Chiu, L.-C., Ju, J.-S., Lin, Y.-C., Fang, Y.-F., Yang, C.-T., & Hsu, P.-C.
(2021). Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines, 9(10), 1122.
https://doi.org/10.3390/vaccines9101122